Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 220

1.

Mortality in an urban cohort of HIV-infected and at-risk drug users in the era of highly active antiretroviral therapy.

Kohli R, Lo Y, Howard AA, Buono D, Floris-Moore M, Klein RS, Schoenbaum EE.

Clin Infect Dis. 2005 Sep 15;41(6):864-72. Epub 2005 Aug 16.

2.

Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.

Wang C, Vlahov D, Galai N, Bareta J, Strathdee SA, Nelson KE, Sterling TR.

J Infect Dis. 2004 Sep 15;190(6):1046-54. Epub 2004 Aug 17.

3.

Trends of mortality and causes of death among HIV-infected patients in Taiwan, 1984-2005.

Yang CH, Huang YF, Hsiao CF, Yeh YL, Liou HR, Hung CC, Yang SY.

HIV Med. 2008 Aug;9(7):535-43. doi: 10.1111/j.1468-1293.2008.00600.x. Epub 2008 Jun 28.

4.

Bacterial pneumonia, HIV therapy, and disease progression among HIV-infected women in the HIV epidemiologic research (HER) study.

Kohli R, Lo Y, Homel P, Flanigan TP, Gardner LI, Howard AA, Rompalo AM, Moskaleva G, Schuman P, Schoenbaum EE; HER Study Group.

Clin Infect Dis. 2006 Jul 1;43(1):90-8. Epub 2006 May 25.

5.

The effect of injecting drug use history on disease progression and death among HIV-positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis.

Murray M, Hogg RS, Lima VD, May MT, Moore DM, Abgrall S, Bruyand M, D'Arminio Monforte A, Tural C, Gill MJ, Harris RJ, Reiss P, Justice A, Kirk O, Saag M, Smith CJ, Weber R, Rockstroh J, Khaykin P, Sterne JA; Antiretroviral Therapy Cohort Collaboration (ART-CC).

HIV Med. 2012 Feb;13(2):89-97. doi: 10.1111/j.1468-1293.2011.00940.x. Epub 2011 Aug 7.

6.

Race and sex differences in antiretroviral therapy use and mortality among HIV-infected persons in care.

Lemly DC, Shepherd BE, Hulgan T, Rebeiro P, Stinnette S, Blackwell RB, Bebawy S, Kheshti A, Sterling TR, Raffanti SP.

J Infect Dis. 2009 Apr 1;199(7):991-8. doi: 10.1086/597124.

7.

Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study.

Palella FJ Jr, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, Holmberg SD; HIV Outpatient Study Investigators.

J Acquir Immune Defic Syndr. 2006 Sep;43(1):27-34.

PMID:
16878047
9.

Determinants of progression to AIDS and death following HIV diagnosis: a retrospective cohort study in Wuhan, China.

Jiang H, Xie N, Cao B, Tan L, Fan Y, Zhang F, Yao Z, Liu L, Nie S.

PLoS One. 2013 Dec 23;8(12):e83078. doi: 10.1371/journal.pone.0083078. eCollection 2013.

10.

A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival.

Mocroft A, Madge S, Johnson AM, Lazzarin A, Clumeck N, Goebel FD, Viard JP, Gatell J, Blaxhult A, Lundgren JD.

J Acquir Immune Defic Syndr. 1999 Dec 1;22(4):369-78.

PMID:
10634199
12.

Postpartum discontinuation of antiretroviral therapy and risk of maternal AIDS-defining events, non-AIDS-defining events, and mortality among a cohort of HIV-1-infected women in the United States.

Melekhin VV, Shepherd BE, Jenkins CA, Stinnette SE, Rebeiro PF, Bebawy SS, Rasbach DA, Hulgan T, Sterling TR.

AIDS Patient Care STDS. 2010 May;24(5):279-86. doi: 10.1089/apc.2009.0283.

13.

Effect of earlier initiation of antiretroviral treatment and increased treatment coverage on HIV-related mortality in China: a national observational cohort study.

Zhang F, Dou Z, Ma Y, Zhang Y, Zhao Y, Zhao D, Zhou S, Bulterys M, Zhu H, Chen RY.

Lancet Infect Dis. 2011 Jul;11(7):516-24. doi: 10.1016/S1473-3099(11)70097-4.

PMID:
21600849
14.

Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.

Patel K, HernĂ¡n MA, Williams PL, Seeger JD, McIntosh K, Van Dyke RB, Seage GR 3rd; Pediatric AIDS Clinical Trials Group 219/219C Study Team.

Clin Infect Dis. 2008 Feb 15;46(4):507-15. doi: 10.1086/526524.

15.

Establishing CD4 thresholds for highly active antiretroviral therapy initiation in a cohort of HIV-infected adult Chinese in Hong Kong.

Wong KH, Chan KC, Cheng KL, Chan WK, Kam KM, Lee SS.

AIDS Patient Care STDS. 2007 Feb;21(2):106-15.

PMID:
17328660
16.
17.

The impact of kidney function at highly active antiretroviral therapy initiation on mortality in HIV-infected women.

Estrella MM, Parekh RS, Abraham A, Astor BC, Szczech LA, Anastos K, Dehovitz JA, Merenstein DJ, Pearce CL, Tien PC, Cohen MH, Gange SJ.

J Acquir Immune Defic Syndr. 2010 Oct;55(2):217-20. doi: 10.1097/QAI.0b013e3181e674f4.

18.

Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies.

Antiretroviral Therapy Cohort Collaboration.

Clin Infect Dis. 2010 May 15;50(10):1387-96. doi: 10.1086/652283.

19.

Predictors of mortality in HIV-1 infected children on antiretroviral therapy in Kenya: a prospective cohort.

Wamalwa DC, Obimbo EM, Farquhar C, Richardson BA, Mbori-Ngacha DA, Inwani I, Benki-Nugent S, John-Stewart G.

BMC Pediatr. 2010 May 18;10:33. doi: 10.1186/1471-2431-10-33.

20.

Incidence, risk factors and causes of death in an HIV care programme with a large proportion of injecting drug users.

Spillane H, Nicholas S, Tang Z, Szumilin E, Balkan S, Pujades-Rodriguez M.

Trop Med Int Health. 2012 Oct;17(10):1255-63. doi: 10.1111/j.1365-3156.2012.03056.x. Epub 2012 Aug 5.

Items per page

Supplemental Content

Write to the Help Desk